GoAI
Get started
Akso Health Group logo

Akso Health Group

AHG

NASDAQHealthcareMedical - Distribution

Open in GoAI

Previous close

$0.9297

−$0.0903 · -8.85%

Aug 21, 4:00 PM ET

AHG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

48

Fair Value

Momentum

30

Weakening

Sentiment

55

Mixed

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People’s Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscopes. In addition, it provides health treatment, consultancy support, and marketing promotion services, as well as technological promotion services and import and export. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Yilin Wang
Listed since
Nov 3, 2017
Employees
12

Market position

Day range

Current $0.9297

52-week range

Current $0.9297

Open
$0.99
Previous close
$1.02
Volume
11.33K
0.32× average
Average volume
35.63K
Average daily volume
Market cap
794M USD
Beta
-1.01
Market reference 1
50-day average
$1.3961
-33.41% below average
200-day average
$1.618
-42.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.52×
P/B (TTM)
3.71×
P/S (TTM)
55.7×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-3.93%
Operating margin
-721.63%
Net margin
-667.88%

Financial health

Debt / equity
0×
Altman Z-score
54.22
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends124%-331%-785%-1239%Gross margin, FY2022: 10.09%Gross margin, FY2023: 9.63%Gross margin, FY2024: 5.06%Gross margin, FY2025: -1.91%Gross margin, FY2026: -0.08%Operating margin, FY2022: -54.34%Operating margin, FY2023: -108.23%Operating margin, FY2024: -357.78%Operating margin, FY2025: -1125.37%Operating margin, FY2026: -28.92%Net margin, FY2022: -280.83%Net margin, FY2023: -10.32%Net margin, FY2024: -391.78%Net margin, FY2025: -913.38%Net margin, FY2026: -134.99%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 10.09%. Gross margin FY2023 9.63%. Gross margin FY2024 5.06%. Gross margin FY2025 -1.91%. Gross margin FY2026 -0.08%. Operating margin FY2022 -54.34%. Operating margin FY2023 -108.23%. Operating margin FY2024 -357.78%. Operating margin FY2025 -1125.37%. Operating margin FY2026 -28.92%. Net margin FY2022 -280.83%. Net margin FY2023 -10.32%. Net margin FY2024 -391.78%. Net margin FY2025 -913.38%. Net margin FY2026 -134.99%.

Income trends

Revenue

13.83M USD-6.40%

Operating income

−4M USD+97.59%

Net income

−18.67M USD+86.17%
Income trends across reported periods32.89M USD−39.55M USD−111.98M USD−184.41M USDRevenue, FY2022: 6M USDRevenue, FY2023: 13.18M USDRevenue, FY2024: 2.41M USDRevenue, FY2025: 14.78M USDRevenue, FY2026: 13.83M USDOperating income, FY2022: −3.26M USDOperating income, FY2023: −14.27M USDOperating income, FY2024: −8.64M USDOperating income, FY2025: −166.3M USDOperating income, FY2026: −4M USDNet income, FY2022: −16.85M USDNet income, FY2023: −1.36M USDNet income, FY2024: −9.46M USDNet income, FY2025: −134.98M USDNet income, FY2026: −18.67M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 6M USD. Revenue FY2023 13.18M USD. Revenue FY2024 2.41M USD. Revenue FY2025 14.78M USD. Revenue FY2026 13.83M USD. Operating income FY2022 −3.26M USD. Operating income FY2023 −14.27M USD. Operating income FY2024 −8.64M USD. Operating income FY2025 −166.3M USD. Operating income FY2026 −4M USD. Net income FY2022 −16.85M USD. Net income FY2023 −1.36M USD. Net income FY2024 −9.46M USD. Net income FY2025 −134.98M USD. Net income FY2026 −18.67M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue13.83M USD14.78M USD2.41M USD13.18M USD6M USD
Cost of goods sold13.84M USD15.06M USD2.29M USD11.91M USD5.39M USD
Gross profit−11.32K USD−281.53K USD122.13K USD1.27M USD605.13K USD
Research and development————421.19K USD
Selling, general, and administrative3.99M USD3.64M USD8.76M USD15.54M USD3.06M USD
Operating expenses3.99M USD166.02M USD8.76M USD15.54M USD3.87M USD
Interest expense————804.14K USD
Depreciation and amortization2.37M USD2.15M USD—18.39K USD18.39K USD
Operating income−4M USD−166.3M USD−8.64M USD−14.27M USD−3.26M USD
Net income−18.67M USD−134.98M USD−9.46M USD−1.36M USD−16.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
60%
3 beats, 2 misses, 0 met estimates
Average EPS surprise
+45.41%
5 comparable reports
Latest EPS result
-0.03

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0-0.12-0.23-0.34Q3 '24BeatQ4 '24BeatQ1 '25MissQ2 '25MissQ3 '25EstimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimate
Q3 2024, reported Jul 30, 2024: actual -0.004, estimate -0.3, surprise +98.70%, Beat. Q4 2024, reported Oct 29, 2024: actual -0.004, estimate -0.3, surprise +98.70%, Beat. Q1 2025, reported Mar 28, 2025: actual -0.2, estimate -0.18, surprise -11.17%, Miss. Q2 2025, reported Apr 30, 2025: actual -0.2, estimate -0.18, surprise -11.17%, Miss. Q3 2025, reported Aug 14, 2025: actual —, estimate -0.18, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual -0.003, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 10, 2026: actual -0.031, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 16, 2026: actual -0.03, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.87M7.56M5.25M2.94MQ4 '24MissQ1 '25MissQ2 '25MissQ3 '25EstimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Oct 29, 2024: actual 3.47M USD, estimate 9.39M USD, surprise -63.08%, Miss. Q1 2025, reported Mar 28, 2025: actual 6.93M USD, estimate 8.42M USD, surprise -17.65%, Miss. Q2 2025, reported Apr 30, 2025: actual 3.92M USD, estimate 8.42M USD, surprise -53.43%, Miss. Q3 2025, reported Aug 14, 2025: actual —, estimate 7.18M USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual 3.5M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 10, 2026: actual 3.42M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 16, 2026: actual 3.42M USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 6.83M USD, estimate —, surprise —, Comparison unavailable.

AHG peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research AHG

research.disclaimer